Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients

European Journal of Heart Failure

Volumn 9, Issue 5, 2007, Pages 518-524

  Pascual Figal, Domingo A ^a   Hurtado Martínez, Jose A ^a   Redondo, Belen ^a   Antolinos, Maria J ^a   Ruiperez, Juan A ^a   Valdes, Mariano ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Acute; Heart failure; Prognosis; Systolic function; Uric acid

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM PHOSPHATE; CHOLESTEROL; CREATININE; FIBRINOGEN; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; SODIUM; TRIACYLGLYCEROL; UREA; URIC ACID; XANTHINE OXIDASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERURICEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; URIC ACID; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34147149642     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.09.001     Document Type: Article

References (40)

1. Heart disease and stroke statistics-2003 update (2002), American Heart Association, Dallas, TX
2. Rich M.W., and NR. Cost-effectiveness analysis in clinical practice. The case of HF. Arch Intern Med 159 (1999) 1690-1700
3. Cowburn P.J., Cleland J.G., Coats A.J., and Komajda M. Risk stratification in chronic heart failure. Eur Heart J 19 (1998) 696-710
4. Cleland J.G., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1. Patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
5. Rich M.W., Beckham V., Wittenberg C., Leven C.L., Freedland K.E., and Carney R.M. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333 (1995) 1190-1195
6. McAlister F.A., Lawson F.M., Teo K.K., and Armstrong P.W. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 110 (2001) 378-384
7. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82 (1990) 1724-1729
8. Jankowska E.A., Ponikowski P., Piepoli M.F., Banasiak W., Anker S.D., and Poole-Wilson P.A. Autonomic imbalance and immune activation in chronic heart failure-pathophysiological links. Cardiovasc Res 70 (2006) 434-445
9. Anker S.D., and Rauchhaus M. Heart failure as a metabolic problem. Eur J Heart Fail 1 (1999) 127-131
10. Leyva F., Chua T.P., Anker S.D., and Coats A.J. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism 47 (1998) 1156-1159
11. Leyva F., Anker S., Swan J.W., et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 18 (1997) 858-865
12. Leyva F., Anker S.D., Godsland I.F., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 19 (1998) 1814-1822
13. Anker S.D., Doehner W., Rauchhaus M., et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107 (2003) 1991-1997
14. Nieminen M.S., Bohm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416
15. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
16. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
17. Quinones M.A., Otto C.M., Stoddard M., Waggoner A., and Zoghbi W.A. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 15 (2002) 167-184
18. Cameron J.S., Moro F., and Simmonds H.A. Uric acid and the kidney. In: Davison A., CJ, Grunfeld J.-P., Kerr D.S., Ritz, and Winearls C.G. (Eds). The Oxford textbook of clinical nephrology (1998), Oxford Medical, Oxford UK 1157-1173
19. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S1-S266
20. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
21. Culleton B.F. Uric acid and cardiovascular disease: a renal-cardiac relationship?. Curr Opin Nephrol Hypertens 10 (2001) 371-375
22. Dobson A. Is raised serum uric acid a cause of cardiovascular disease or death?. Lancet 354 (1999) 1578
23. Johnson R.J., and Tuttle K.R. Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. Hypertension 35 (2000) E10
24. Alderman M.H., Cohen H., Madhavan S., and Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34 (1999) 144-150
25. Bettencourt P., Ferreira A., Dias P., et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail 6 (2000) 306-313
26. Batin P., Wickens M., McEntegart D., Fullwood L., and Cowley A.J. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 16 (1995) 1613-1618
27. Bakhtiiarov Z.A. Changes in xanthine oxidase activity in patients with circulatory failure. Ter Arkh 61 (1989) 68-69
28. Hare J.M., and Johnson R.J. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 107 (2003) 1951-1953
29. Jarasch E.D., Bruder G., and Heid H.W. Significance of xanthine oxidase in capillary endothelial cells. Acta Physiol Scand Suppl 548 (1986) 39-46
30. Berry C.E., and Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555 (2004) 589-606
31. Rao G.N., Corson M.A., and Berk B.C. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266 (1991) 8604-8608
32. Shi Y., Evans J.E., and Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003) 516-521
33. Netea M.G., Kullberg B.J., Blok W.L., Netea R.T., and van der Meer J.W. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 89 (1997) 577-582
34. Doehner W., Schoene N., Rauchhaus M., et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105 (2002) 2619-2624
35. Johnson R.J., Kivlighn S.D., Kim Y.G., Suga S., and Fogo A.B. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 33 (1999) 225-234
36. Leyva F., Wingrove C.S., Godsland I.F., and Stevenson J.C. The glycolytic pathway to coronary heart disease: a hypothesis. Metabolism 47 (1998) 657-662
37. Doehner W., Rauchhaus M., Florea V.G., et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J 141 (2001) 792-799
38. Cicoira M., Zanolla L., Rossi A., et al. Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 143 (2002) 1107-1111
39. Roch-Ramel F., Guisan B., and Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 280 (1997) 839-845
40. Kogler H., Fraser H., McCune S., Altschuld R., and Marban E. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res 59 (2003) 582-592